-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The latest news refers to the medical insurance negotiations in 2022 are expected to start in November, and who can finally be "insured" for 143 exclusive western drugs (including chemical drugs and biological drugs) outside the catalogue has attracted much attention
.
According to data from Intranet, more than 290 of the exclusive western medicines in the 2021 edition of the medical insurance catalogue have exceeded 100 million yuan in terminal sales in China's public medical institutions, and more than 70% of products have maintained positive growth in the first half of 2022
.
Medical insurance helps take off, and domestic exclusive products are rising amazingly
.
Awesome! Shi Yao topped the list of more than 1 billion, and the explosive models of Innovda, Hengrui and Chia Tai Tianqing will add new impetus Table 1: Exclusive Western medicines (including chemical and biological drugs) with terminal sales of more than 1 billion yuan in China's public medical institutions in 2021 Note: According to the product name, * there is a limited scope of use for medical insurance catalogue Butylphthalide sodium chloride injection and butyphthalide soft capsules of CSPC Enbip Pharmaceutical, paclitaxel liposomes for injection from Nanjing Luye Pharmaceutical, Goserelin acetate sustained-release implant from AstraZeneca, alteplase for injection from Boehringer Ingelheim, Five exclusive products have passed the 2022 medical insurance catalogue adjustment form review, and products that fall under condition 1 in the catalogue (the agreement expires at the end of 2022) will participate in the renewal negotiations
.
Figure 1: Sales of butylphthalide series products (10,000 yuan) Source: Intranet terminal competition pattern of China's public medical institutions In 2021, Shiyao's butylphthalide sodium chloride injection has become the best-selling medical insurance exclusive western medicine
in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions).
。 The product has previously entered the supplementary catalogue of many provinces, and after entering the national medical insurance catalogue in 2017, sales have maintained rapid growth, and sales have exceeded 3.
9 billion yuan in 2020, and the growth rate has slowed down but maintained positive growth after entering the 2020 version of the negotiation directory, winning more than 4.
1 billion yuan in sales in 2021, and the growth rate has returned to double digits in the first half of 2022, with sales exceeding 2.
4 billion yuan
.
AstraZeneca's goserelin acetate sustained-release implant is a first-line drug for the treatment of prostate cancer, as a sustained-release implant of peptide hormones, its preparation technology, equipment, drug delivery devices and other requirements are very high, so far no generic drugs have been approved
in the domestic market.
After entering the national medical insurance directory in 2009, the product maintained rapid growth, with sales exceeding 3.
3 billion yuan in 2020, and the growth rate began to slow down after entering the 2020 version of the negotiation directory, with sales exceeding 3.
4 billion yuan in 2021 and exceeding 1.
6 billion yuan
in the first half of 2022.
There are 10 exclusive products of more than 1 billion yuan that fall under condition 2 of the catalogue (new indications or renewal drugs to adjust the scope of medical insurance payment), including 8 anti-tumor drugs, and it has become a necessary means
to create a large variety by adapting to the continuous expansion of drug groups and extending the life cycle of products 。 According to data from Intranet, in recent years, anti-tumor drugs have maintained a rapid growth trend in China's public medical institutions, and the market size in 2021 has exceeded 110 billion yuan, and antibody drugs and protein kinase inhibitors have become the most popular subcategories, with a total market share of more than 60%
in the first half of 2022 。 Figure 2: Sales of three domestic anti-tumor antibody drugs (10,000 yuan) Source: Intranet terminal competition pattern of China's public medical institutions Innovent 's sindilimab injection entered the negotiation directory in 2019, the indication is Hodgkin lymphoma, the terminal sales in China's public medical institutions exceeded 2.
8 billion yuan in 2021, and the 2021 version of the negotiation catalog added indications for non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, and hepatocellular carcinoma, and sales in the first half of 2022 have reached 1.
18 billion yuan
。 In this year's medical insurance negotiations, the product is expected to be added to the indications for esophageal squamous
cell carcinoma, gastric and gastroesophageal junction adenocarcinoma.
Hengrui's carrelizumab for injection entered the negotiation directory in 2020, and its indications include Hodgkin lymphoma, hepatocellular carcinoma, non-squamous non-small cell lung cancer, and esophageal squamous cell carcinoma, with sales rising to more than 2.
5 billion yuan in 2021 and maintaining double-digit growth
in the first half of 2022.
It is reported that the indications for the product to participate in medical insurance negotiations this year may involve nasopharyngeal carcinoma, esophageal squamous cell carcinoma (first-line), and squamous non-small cell lung cancer (first-line).
BeiGene's tislelizumab injection entered the negotiation catalog in 2020, with indications for Hodgkin lymphoma and urothelial carcinoma, and sales in 2021 have exceeded 1.
1 billion yuan, and the 2021 version of the negotiation catalog has added indications for non-small cell lung cancer and hepatocellular carcinoma, and sales have exceeded 1.
2 billion yuan
in the first half of 2022.
It is reported that the product's advanced lung cancer (second/third line), esophageal squamous cell carcinoma, nasopharyngeal carcinoma (first-line) and MSI-H/dMMR solid tumors are expected to participate in this year's medical insurance negotiations
。 Figure 3: Sales of two domestic anti-tumor protein kinase inhibitors (10,000 yuan) Source: Intranet terminal competition pattern of China's public medical institutions CP Tianqing Pharmaceutical Group's anlotinib hydrochloride capsules 2017 version of the negotiation directory is indicated for non-small cell lung cancer, sales in 2020 exceeded 3.
4 billion yuan, the 2020 version of the negotiation directory added soft tissue sarcoma, small cell lung cancer, sales rose to more than 3.
7 billion yuan in 2021, the 2021 version of the negotiation directory added medullary thyroid cancer, Sales in the first half of 2022 have exceeded CNY 1.
6 billion
.
In April this year, the product was approved
for a new indication for differentiated thyroid cancer.
Hengrui's pyrrotinib maleate tablets entered the negotiation directory in 2019, with HER2-positive recurrent or metastatic breast cancer (second-line), with sales of more than 1.
5 billion yuan in 2021 and more than 700 million yuan in the first half of 2022
.
At the end of May this year, the new adaptation of the product to HER2-positive early or locally advanced breast cancer neoadjuvant therapy was approved
.
Sales of more than 20 exclusive products continue to soar, Simcere, Haosen, and East China are full of fire Table 2: Exclusive products (including chemical drugs and biological drugs) with sales of more than 100 million in 2021 and a continuous growth rate of more than 100% Note: According to the product name, * is the limited scope of use of the medical insurance catalogue Among the more than 290 medical insurance exclusive western medicines included in the statistical scope this time, the highest sales growth rate in 2021 is Hainan Simcere Pharmaceutical's edaravone dextrol injection concentrated solution
。 The product was approved for listing in July 2020, entered the negotiation catalog in the same year, and won more than 1.
4 billion yuan in sales with a growth rate of 28,582% in 2021, becoming a new 1 billion brand that year, with a growth rate of 228% in the first half of 2022, and sales have exceeded 1 billion yuan, becoming the TOP8 terminal nervous system drug products
in China's public medical institutions 。 Figure 4: Sales of Haosen's three continuously soaring products (10,000 yuan) Source: Intranet terminal competition pattern of China's public medical institutions Omegatinib mesylate tablets were approved for listing in 2020, entered the negotiation catalog in the same year, and sales soared to more than 800 million yuan in 2021, won 750 million yuan in the first half of 2022, and are expected to break through the 1 billion yuan mark
this year 。 At the end of last year, the product was approved for a new indication "for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R replacement mutations" and is expected to participate in this year's medical insurance negotiations
.
Flumatinib mesylate tablets and polyethylene glycol rossenamide injection are both new products approved in 2019, both entered the negotiation catalog in 2020, and sales exceeded 100 million yuan in 2021, and sales in the first half of 2022 have exceeded the whole year of last year
.
The two products have also entered this year's medical insurance catalogue adjustment form review and will participate in renewal negotiations
.
It is also worth mentioning the indobufen tablets in East China, China, and the United States, which has earlier entered the supplementary catalogue of many provinces, and the sales of terminals in public medical institutions in China in 2016 were less than 10 million yuan
.
Since 2017, the sales of the product have continued to soar after being "promoted" to the national medical insurance directory, exceeding 200 million yuan for the first time in 2020, reaching a new peak of 500 million yuan in 2021, and also winning 510 million yuan in sales in the first half of 2022, and becoming the top 10 terminal antithrombotic drugs in
China's public medical institutions.
Conclusion Every adjustment of the national medical insurance catalogue can be called the highlight of the pharmaceutical industry, which has aroused widespread concern
in the society.
Especially in recent years, it has entered the normalization stage of "annual adjustment", and the time interval between newly launched products entering medical insurance has been greatly shortened, which not only improves the accessibility of patients' medications, but also helps products achieve rapid volume
.
The R&D level of domestic pharmaceutical companies continues to improve, more and more new drugs and exclusive products are launched, and obtaining medical insurance assistance has become the best means to realize the value of products, and more domestic super varieties may emerge in the future, continuously improving the overall level of
China's pharmaceutical industry.
Source: Intranet database Note: Intranet "Terminal Competition Pattern of China's Public Medical Institutions", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
